Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-02-17

Clinical Trial Update: Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating hydroxychloroquine with phlebotomy for porphyria cutanea tarda has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: The University of Texas Medical Branch, Galveston | Conditions: Porphyria Cutanea Tarda | Phase 2 | Status: COMPLETED | Results posted: 2023-02-17